OVEMP in Myasthenia

Sponsor
University of Zurich (Other)
Overall Status
Completed
CT.gov ID
NCT03049956
Collaborator
(none)
96
1
1

Study Details

Study Description

Brief Summary

Myasthenia gravis is an autoimmune disorder of neuromuscular transmission, characterized by fluctuating muscle weakness and fatigability. In isolated ocular myasthenia, when only the extraocular muscles are involved, most common ancillary tests, such as acetylcholine receptor autoantibodies and repetitive nerve stimulation, are often negative.

A simple, quick and non-invasive test for ocular myasthenia based on ocular vestibular evoked myogenic potentials (oVEMP) was recently developed.

The main goal of the study is to validate repetitive oVEMP stimulation in a blinded diagnostic accuracy study in order to facilitate early and accurate diagnosis of ocular myasthenia.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Ocular vestibular evoced myogenic potentials
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
96 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking Description:
Blinded diagnostic accuracy study (index test vs. reference standard).
Primary Purpose:
Diagnostic
Official Title:
Diagnostic Accuracy of Repetitive Ocular Vestibular Evoked Myogenic Potentials in Myasthenia Gravis (OMG Study)
Actual Study Start Date :
Nov 1, 2016
Actual Primary Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients with clinical suspicion of ocular myasthenia gravis

Diagnostic Test: Ocular vestibular evoced myogenic potentials
The oVEMP technique is an accepted standard for testing otolith function in vestibular patients. It represents a quick, simple and non-invasive technique utilizing repetitive stimulation of the otolith organs with bone-conducted vibration to elicit an extraocular muscle response. Repetitive oVEMP stimulation leads to a characteristic decrement in patients with myasthenia, which can be quantified with surface electromyography from the inferior oblique muscle underneath the eye.

Outcome Measures

Primary Outcome Measures

  1. Decrement (as quantified in %) of repetitive 20 Hz ocular vestibular-evoked myogenic potentials (oVEMP) [The primary outcome measure (index test oVEMP) will be assessed at baseline, in conjunction with reference standard/standard clinical workup (including blood analysis, neurological exam, edrophonium test, electromyography, single-fiber electromyography).]

    oVEMP have been established as a standard clinical test of otolith function. Based on this technique, repetitive oVEMP stimulation, as a novel method for detecting ocular myasthenia gravis, was recently developed. Using this method, a response decrement in extraocular muscles can be quantified. The method is based on the conventional oVEMP montage with surface electrodes placed below the eyes. In order to elicit a response decrement, trains of ten bone-conducted vibration bursts at repetition rates of 20Hz will be applied with a hand-held 'minishaker' to the forehead. The oVEMP in response to these repetitive vibration stimuli will be measured in sustained upgaze from both inferior oblique muscles via surface electrodes. The magnitude of the decrement will be calculated as the difference between the amplitude of the second stimulus repetition and the mean amplitude of the fifth to ninth stimulus repetition. For further Information see: Valko et al. 2016 PMID:26791146

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Informed Consent as documented by signature

  • Patients with diplopia and/or ptosis suspicious for myasthenia gravis.

Exclusion Criteria:
  • Vestibular disorders

  • Significant systemic myasthenia symptoms (respiration or swallowing difficulties) unable to undergo oVEMP testing.

  • Patients with significant cardiac or respiratory disease will be excluded from the Tensilon test as part of the reference standard.

  • Women who are pregnant or breast feeding.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital Zurich, Ophthalmology/Neurology Department Zurich Switzerland 8091

Sponsors and Collaborators

  • University of Zurich

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Konrad Peter Weber, PD Dr.med., University of Zurich
ClinicalTrials.gov Identifier:
NCT03049956
Other Study ID Numbers:
  • 2016-01109
First Posted:
Feb 10, 2017
Last Update Posted:
Jan 11, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Konrad Peter Weber, PD Dr.med., University of Zurich
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 11, 2021